Professional Documents
Culture Documents
FERROUS SULFATE
CLASSIFICATION: Antianemic, iron
ACTION: Normal daily intake males 12-20 mg; females 8-15 mg;
only 10% absorbed; Iron absorbed by from duodenum and upper
jejunum by active mechanism thru mucosal cells, combines with
transferring; iron stored as hemosiderin or aggregated ferritin cells
of liver, spleen, bone marrow; 2/3 of iron in circulating RBCs
INDICATIONS: Prophylaxis, treatment of iron deficiency and irondeficiency anemias; dietary supplement for iron
USUAL DOSAGE: Adults 300 mg/day
ADVERSE REACTIONS: Constipation, gastric irritation, nausea,
abdominal cramps, anorexia, diarrhea, dark-colored stools
NURSING CONSIDERATIONS: Substitution of one iron salt for
another without proper adjustment may result in serious over or
under dosing; Eggs, milk, coffee or tea may significantly inhibit iron
absorption.
AMOXICILLIN
CLASSIFICATION: Antibiotic, penicillin
ACTION: Synthetic broad-spectrum penicillin closely related to
ampicillin; Binds to bacterial cell wall (PBP-1 and PBP-3; penicillinbinding sites), causing cell death by inhibiting cell wall synthesis;
bactericidal action; spectrum is larger than penicillins
INDICATIONS: Ear, nose, and throat infections.
USUAL DOSAGE:
Over 40 kg: 500 mg q8hr or 500 mg q12hr; under 40 kg:
20mg/kg/day in divided doses q8hr
ADVERSE REACTIONS: Hypersensitivity, nausea & vomiting,
gastritis, stomatitis.
ACETAMINOPHEN
CLASSIFICATION: non-narcotic analgesic
HYDROCHLOROTHIAZIDE
CLASSIFICATION: Antihypertensive, combination drug
ACTION: acts directly on the distal tubule to promote the excretion
of sodium, bicarbonate, chloride, and fluid; Increases urinary pH;
Hydrochlorothiazide promotes excretion of sodium and chloride and thus
water by distal renal tubule; Also increases excretion of potassium and
smaller amounts of bicarbonate; Antihypertensive effects due to direct
dilation of arterioles as well as fluid volume loss
INDICATIONS: Hypertension or edema in clients who manifest
hypokalemia on hydrochlorothiazide alone; in clients requiring a diuretic
and in whom hypokalemia cannot be risked; usually not first line of
therapy except when avoiding hypokalemia
ADVERSE REACTIONS: Nausea & vomiting, headache, anorexia, GI
upset, diarrhea, flatulence, dizziness, photosensitivity
Atenolol (Tenormin)
CLASSIFICATION: Beta-Blocker
ACTION: In therapeutic doses, atenolol selectively blocks beta1adrenergic receptors located chiefly in cardiac muscle.
INDICATIONS used to treat high blood pressure. It is also used to treat
angina and chest pain.
ADVERSE REACTIONS: Constipation, indigestion, dry mouth, dizziness
NURSING CONSIDERATIONS: Check apical pulse before giving oral
drug, especially in patients receiving digitalis (both drugs slow AV
conduction). If below 60 bpm (or other ordered parameter), withhold dose
and consult physician. Monitor apical pulse, BP, respirations, and
DICLOFENAC SODIUM
CLASSIFICATION: CENTRAL NERVOUS SYSTEM AGENT; ANALGESIC,
ANTIPYRETIC; NSAID
ACTION: Although its exact mechanism of action has not been fully
elucidated, it appears to be a potent inhibitor of cyclooxygenase, thereby
decreasing the synthesis of prostaglandins.
INDICATIONS Analgesic and antipyretic effects in symptomatic treatment
of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Also
acute gout.
1)
2)
3)
4)
5)
6)
7)
Collaboration:
- Monitor laboratory tests: electrolytes, creatinine
Rational: control of renal dysfunction
HEPARIN
CLASSIFICATION: Heparin, Anticoagulant
ACTION: Does not dissolve previously formed clots, but forestalls enlargement and prevents new clots
from forming; Potentiates inhibitory action of antithrombin III; Occurs due to formation of a complex
with antithrombin III and causing a conformational change in antithrombin III molecule; Action of
thrombin in coagulation is inhibited; Also prevents formation of a stable fibrin clot by inhibiting the
activation of fibrin-stabilizing factor by thrombin
INDICATIONS: Pulmonary/peripheral arterial embolism; Prophylaxis and treatment of venous
thrombosis and extensions; Atrial fibrillation with embolization; Treatment and diagnosis of DIC; in low
doses to prevent DVT and PE in pregnant clients with thromboembolism history and others;
Prophylaxis of clotting in blood transfusions and others
ADVERSE REACTIONS: Hemorrhage ranging from minor local ecchymoses to major hemorrhagic
complications from any organ, chills, fever, urticaria, local irritation, erythema, mild pain, hematoma
INTERACTIONS:
Oralanticoagulants/dipyridamole/hydroxychloroquine/ibuprofen/indomethacin/NSAIDs/ticlopidine
ACTION: Decreases hepatic glucose production, decreases intestinal absorption of glucose, increases
peripheral uptake and utilization of glucose; does not cause hypoglycemia in either diabetic or non
diabetic clients, and does not cause hyperinsulinemia; insulin secretion remains unchanged, while
fasting insulin levels and day-long plasma insulin response may decrease
INDICATIONS: As monotherapy, as adjunct to diet and exercise, to improve glycemic control in clients
with type 2 diabetes; Immediate-release tablets and PO solution can be used in clients 10 yrs and
older; Extended Release form used to treat type 2 diabetes as initial therapy or in conjunction with a
sulfonylurea or insulin in clients 17 y/o and older
ADVERSE REACTIONS: Lactic acidosis, hypoglycemia, diarrhea, nausea & vomiting, asthenia,
flatulence, headache, abdominal pain/discomfort
NURSING CONSIDERATIONS: Lactic acidosis is a rare, but serious, metabolic complication that can
occur due to metformin accumulation (50 % fatal); do not confuse Glucophage with Glucovance;
individualize dosage based on tolerance and effectiveness; give with meals and start at a low dose
with gradual escalation (will reduce GI side effects); may safely switch
from metformin to metformin extended-release; may cause a metallic taste (will subside)
GENERIC NAME: Candesartan
CLASSIFICATION: ARB
ACTION: Angiotensin II receptor (type AT1) antagonist. Angiotensin II is a potent vasoconstrictor and
primary vasoactive hormone of the reninangiotensinaldosterone system. Candesartan selectively
blocks binding of angiotensin II to the AT1 receptors found in many tissues (e.g., vascular smooth
muscle, adrenal glands).
INDICATIONS Treating high blood pressure alone or with other medicines. It is used in certain
patients to treat heart failure. It may also be used for other conditions as determined by your doctor.
Candesartan is an angiotensin II receptor blocker (ARB). It works by relaxing blood vessels. This helps
to lower blood pressure.
ADVERSE REACTIONS: upper respiratory tract infection, dizziness, back pain, pharyngitis, and rhinitis
NURSING CONSIDERATIONS: Monitor BP as therapeutic effectiveness is indicated by decreases in
systolic and diastolic BP within 2 wk with maximal effect at 46 wk. Monitor for transient hypotension
in volume/salt-depleted patients; if hypotension occurs, place in supine position and notify physician.
Monitor BP periodically; trough readings, just prior to the next scheduled dose, should be made when
possible. Lab tests: Periodically monitor BUN and creatinine, serum potassium, liver enzymes, and CBC
with differential.
possible. Lab tests: Periodically monitor BUN and creatinine, serum potassium, liver enzymes, and CBC
with differential.
Hypromellose Eye Drops
Hydromoor eye drops contain the active ingredient hypromellose, which is a type of medicine known
as an eye lubricant. (NB. Hypromellose eye drops are also available without a brand name, ie as the
generic medicine.)
Hypromellose is a synthetic polymer that forms a film on the surface of the eye (cornea). It produces a
transparent, lubricating and moistening film on the surface of the eye and is used as artificial tears.
Hypromellose eye drops provide soothing relief from the symptoms of dry eyes, such as soreness,
irritation or a gritty sensation. These may be caused by your eye not producing enough tears to keep
the eye moist, or by things such as certain medical conditions or treatments, prolonged use of
computer screens (where you tend to blink less and thus not lubricate the eyes sufficiently), or drying
atmospheric conditions such as air-conditioning, central heating or atmospheric pollution.
food to decrease GI upset; do not share drugs; keep in safe place; drug may cause dizziness and
drowsiness; may cause constipation, nausea& vomiting, rash/itching, and physical dependence; avoid
alcohol and any other CNS depressants without provider approval; tolerance may occur
ONDANSETRON HYDROCHLORIDE
CLASSIFICATION: Antiemetic
ACTION: Cytotoxic chemotherapy is thought to release serotonin from enterochromaffin cells of the
small intestine; the released serotonin may stimulate the vagal afferent nerves through the 5-HT3
receptors, thus stimulating the vomiting reflex; Ondansetron, a 5-HT3 antagonist, blocks this effect of
serotonin; whether the drug acts centrally and/or peripherally to antagonize the effect of serotonin is
not known
INDICATIONS: Prevent N&V resulting from initial and repeated courses of cancer chemotherapy,
including cisplatin, greater than 50 mg/m2; prevent N&V associated with initial and repeat courses of
moderately emetogenic cancer chemotherapy; Prevent N&V associated with radiotherapy in clients
receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to
the abdomen
ADVERSE REACTIONS: Diarrhea, headache, dizziness, malaise/fatigue, constipation, bradycardia,
hypotension, drowsiness/ sedation, anxiety/agitation, gynecological disorder, urinary retention,
hypoxia, pruritus, pyrexia, shivers
NURSING CONSIDERATIONS: Do not confuse Zofran with Zoloft, Zantac, or Zosyn; do not exceed 8 mg
PO or 8 mg IV daily with impaired hepatic function; 2 mg/mL Ondansetron injection requires no dilution
for administration for postop N&V; inspect visually for particulate matter and discoloration before
administering; drug is to prevent N&V; to be given exactly as prescribed; may cause drowsiness or
dizziness; do not perform activities that require mental alertness until drug effects realized; report any
rash, diarrhea, constipation, altered respirations (brochospasms), or loss of response
ALENDRONATE
CLASSIFICATION: BISPHOSPHONATE; REGULATOR, BONE METABOLISM
ACTION: Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption.
Antiresorption mechanism is not fully understood. It does, however, localize preferentially to resorption
sites of active bone turnover and has minimal to no interference with bone mineralization.
INDICATIONS: Prevention and treatment of osteoporosis in postmenopausal women, Paget's disease.
Treatment of glucocorticoid-induced osteoporosis.
ADVERSE REACTIONS Endocrine: Hypocalcemia, hypophosphatemia. GI: Esophageal irritation
and ulceration, nausea, vomiting, abdominal pain, dyspepsia, diarrhea, constipation,
flatulence. Other: Arthralgias, myalgias, headache, rash.
INTERACTIONS Drug: Ranitidine increases alendronate availability. Food: Calcium and food
(especially dairy products) reduce alendronate absorption.
CLOTRIMAZOLE
CLASSIFICATION: ANTIINFECTIVE; ANTIBIOTIC; ANTIFUNGAL
ACTION: Has broad-spectrum fungicidal activity. Acts by altering fungal cell membrane permeability,
permitting loss of phosphorous compounds, potassium, and other essential intracellular constituents
with consequent loss of ability to replicate.
INDICATIONS: Dermal infections including tinea pedis, tinea cruris, tinea corporis, tinea versicolor;
also vulvovaginal and oropharyngeal candidiasis.
ADVERSE REACTIONS GI: Abnormal liver function tests; occasional nausea and vomiting (with oral
troche). Skin: Stinging, erythema, edema, vesication, desquamation, pruritus, urticaria, skin
fissures. Urogenital: Mild burning sensation, lower abdominal cramps, bloating, cystitis, urethritis, mild
urinary frequency, vulval erythema and itching, pain and vaginal soreness during intercourse
INTERACTIONS Drug: Intravaginal preparations may inactivate SPERMICIDES.
CONTRAINDICATIONS: Ophthalmic uses; systemic mycoses. Safe use during pregnancy (category C
for oral troches, category B for topical preparations), lactation, and in children <3 y not established
NURSING CONSIDERATIONS:
Evaluate effectiveness of treatment. Report any signs of skin irritation with dermal
preparations.
Anticipate signs of clinical improvement within the first week of drug use.